Anticoagulation for heart failure: Selecting the best therapy

Shun Kohsaka, Shunichi Homma

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Heart failure (HF) incidence approaches 10 per 1000 population after the age of 65 years, and is the most common Medicare diagnosis. The management of HF patients has improved over the last decade, but the risk of thromboembolic complications is frequently underestimated and currently, no treatment options have been formally implemented to decrease the incidence of events. In particular, stroke is a major complication of HF. HF ranks second after atrial fibrillation in the number of cardiogenic strokes caused. The actual rate of stroke in recent HF trials ranges between 1.5 and 2.4% per year. Warfarin is of proven efficacy in patients with ischemic heart disease and atrial fibrillation, but there has been little research testing antithrombotic agents in patients with HF. Aspirin may be another promising drug, but trials have shown a higher rate of HF admissions with aspirin, suggesting that aspirin may attenuate the angiotensin-converting enzyme inhibitor effect on cardiac function. We eagerly await the completion of large, randomized trials to help guide us in these important issues affecting a large number of patients.

Original languageEnglish
Pages (from-to)1209-1217
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Issue number10
Publication statusPublished - 2009 Oct


  • Aspirin
  • Atrial fibrillation
  • Heart failure
  • Left ventricular aneurysm
  • Left ventricular systolic dysfunction
  • Stroke
  • Thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Anticoagulation for heart failure: Selecting the best therapy'. Together they form a unique fingerprint.

Cite this